JP2009510044A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510044A5
JP2009510044A5 JP2008532874A JP2008532874A JP2009510044A5 JP 2009510044 A5 JP2009510044 A5 JP 2009510044A5 JP 2008532874 A JP2008532874 A JP 2008532874A JP 2008532874 A JP2008532874 A JP 2008532874A JP 2009510044 A5 JP2009510044 A5 JP 2009510044A5
Authority
JP
Japan
Prior art keywords
mammal
inflammatory
allergic
methyl
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008532874A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510044A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2006/003627 external-priority patent/WO2007036734A1/en
Publication of JP2009510044A publication Critical patent/JP2009510044A/ja
Publication of JP2009510044A5 publication Critical patent/JP2009510044A5/ja
Pending legal-status Critical Current

Links

JP2008532874A 2005-09-29 2006-09-29 ピラゾロ[3,4−b]ピリジン化合物及びそのPDE4阻害薬としての使用 Pending JP2009510044A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72159705P 2005-09-29 2005-09-29
PCT/GB2006/003627 WO2007036734A1 (en) 2005-09-29 2006-09-29 Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor

Publications (2)

Publication Number Publication Date
JP2009510044A JP2009510044A (ja) 2009-03-12
JP2009510044A5 true JP2009510044A5 (enExample) 2009-11-05

Family

ID=37685723

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008532874A Pending JP2009510044A (ja) 2005-09-29 2006-09-29 ピラゾロ[3,4−b]ピリジン化合物及びそのPDE4阻害薬としての使用
JP2008532873A Expired - Fee Related JP5323484B2 (ja) 2005-09-29 2006-09-29 ピラゾロ[3,4−b]ピリジン化合物及びそのPDE4阻害薬としての使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008532873A Expired - Fee Related JP5323484B2 (ja) 2005-09-29 2006-09-29 ピラゾロ[3,4−b]ピリジン化合物及びそのPDE4阻害薬としての使用

Country Status (7)

Country Link
US (2) US20080255186A1 (enExample)
EP (2) EP1940835B1 (enExample)
JP (2) JP2009510044A (enExample)
AT (1) ATE503756T1 (enExample)
DE (1) DE602006021044D1 (enExample)
ES (1) ES2363795T3 (enExample)
WO (2) WO2007036734A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007036734A1 (en) * 2005-09-29 2007-04-05 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
GB0614570D0 (en) * 2006-07-21 2006-08-30 Glaxo Group Ltd Compounds
US8003663B2 (en) * 2006-08-01 2011-08-23 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
CN103497185A (zh) * 2007-03-14 2014-01-08 兰贝克赛实验室有限公司 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
EP2141150B1 (en) 2007-04-26 2013-12-11 Takeda Pharmaceutical Company Limited Bicyclic compound and pharmaceutical use thereof
EP2249646A4 (en) * 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
WO2009100170A1 (en) * 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
AU2009306026A1 (en) * 2008-09-19 2010-04-29 Ranbaxy Laboratories Limited Phosphodiestarase inhibitors
CN102348707A (zh) 2009-01-13 2012-02-08 葛兰素集团有限公司 作为syk激酶抑制剂的嘧啶甲酰胺衍生物
WO2011113512A1 (de) * 2010-03-16 2011-09-22 Merck Patent Gmbh Morpholinylchinazoline
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
WO2012061926A1 (en) * 2010-11-08 2012-05-18 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
EP2574607A1 (en) * 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
CA2903572A1 (en) * 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
RS59007B1 (sr) 2014-02-03 2019-08-30 Vitae Pharmaceuticals Llc Dihidropirolopiridinski inhibitori ror-gama
DE102014009164A1 (de) * 2014-06-03 2015-12-03 Herbalist & Doc Gesundheitsgesellschaft Mbh Silikonölhaltige nasal anzuwendende Formulierungen
EA031967B1 (ru) 2014-10-14 2019-03-29 Вайтаи Фармасьютиклз, Инк. ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
KR20180086221A (ko) 2015-11-20 2018-07-30 비타이 파마슈티컬즈, 인코포레이티드 Ror-감마의 조절물질
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ROR-γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US20200087271A1 (en) 2016-12-20 2020-03-19 Syngenta Participations Ag N-cyclobutyl-thiazol-5-carboxamides with nematicidal activity
CA3056886A1 (en) * 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
AR112346A1 (es) * 2017-08-10 2019-10-16 Lilly Co Eli Derivados de [1,2,4]triazolo
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
AU2019383976B2 (en) 2018-11-19 2025-07-03 Bt Bidco, Inc. Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN115335043B (zh) * 2020-01-23 2025-03-28 迈欧伏特治疗公司 Pgdh抑制剂以及制备和使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2331119T3 (es) * 2002-09-16 2009-12-22 Glaxo Group Limited Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa.
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2007036734A1 (en) * 2005-09-29 2007-04-05 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor

Similar Documents

Publication Publication Date Title
JP2009510044A5 (enExample)
RU2500681C2 (ru) Замещенные гетероциклом пиперазинодигидротиенопиримидины
MY167423A (en) Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use
JP2018513107A5 (enExample)
JP2013526609A5 (enExample)
NO20076561L (no) Imidazoquinoliner som lipid kinaseinhibitorer
JP2014506321A5 (enExample)
JP6642914B2 (ja) アルキルエーテル誘導体またはその塩を含有する神経損傷後のリハビリテーション効果促進剤
JP2012520249A5 (enExample)
JP2009533356A5 (enExample)
JP2007533687A5 (enExample)
JP2017528507A5 (enExample)
JP2005506370A5 (enExample)
RU2015117267A (ru) Замещенные соединения амида
UY37328A (es) Compuestos diazaheterobicíclicos sustituidos y su uso
JP2015522018A5 (enExample)
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
JP2015502974A5 (enExample)
JP2016503010A5 (enExample)
JP2017503798A5 (enExample)
JP2016540749A5 (enExample)
JP2010529969A5 (enExample)
JP2018537513A5 (enExample)
JP2020524689A5 (enExample)
JP2024160326A (ja) Eaat2活性化因子およびその使用方法